RxDoctor Payments Data

Bipasha Mitra, MD

Family Medicine · Wilmington, DENPI 1831371574

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.

$6,148in general payments, 2019–2025

Across 377 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$779
  • Novo Nordisk$643
  • AbbVie$579
  • AstraZeneca$510
  • Lilly USA, LLC$389
  • GSK$361
  • plus $3K from 46 others

What the payments were for

  • Consulting fees$250%
  • Food & beverage$6,123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,148 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$219,583
Medicare patients
318
Services billed
3,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$59,341
JanuviaSitagliptin Phosphate17$27,552
TrulicityDulaglutide15$26,285
EliquisApixaban30$22,299
Breo ElliptaFluticasone/Vilanterol16$16,817
FarxigaDapagliflozin Propanediol13$10,916
Duloxetine Hcl86$4,332
SynthroidLevothyroxine Sodium71$4,151
Atorvastatin Calcium305$3,669
Rosuvastatin Calcium162$3,385
Bupropion XlBupropion Hcl56$2,518
Levothyroxine Sodium219$2,388
Venlafaxine Hcl ErVenlafaxine Hcl18$2,062
Amlodipine Besylate176$2,053
Metoprolol Succinate121$2,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$265$59,34138 claims
MerckJanuvia$155$27,55217 claims
Lilly USA, LLCTrulicity$389$26,28515 claims
PfizerEliquis$32$22,29930 claims
GSKBreo Ellipta$361$16,81716 claims
AstraZenecaFarxiga$510$10,91613 claims
AbbVieSynthroid$579$4,15171 claims
Almatica Pharma LLCSertraline Hcl$17$1,106111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →